文献速递炎症性肠病

荟萃分析:英夫利西单抗静脉给药与皮下给药在炎症性肠病中的比较

Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease.
PubMed 文献 · Aliment Pharmacol Ther · 2025-07-10

该系统综述与网状荟萃分析纳入9项研究共2519例炎症性肠病患者(克罗恩病846例,溃疡性结肠炎1673例),比较静脉与皮下英夫利西单抗在第30周和第54周的疗效。SUCRA分析中皮下制剂在所有比较中排名第一;后验概率模型显示皮下制剂在临床应答(30周)和临床缓解(30周及54周)方面有强或极强 superiority 证据,但对比图分析中无一比较达到统计学显著。

要点

  • 皮下英夫利西单抗在临床应答(30周)和临床缓解(30周及54周)方面有强或极强 superiority 证据。
  • 第54周临床应答方面皮下制剂仅有中等强度证据,内镜缓解(54周)无任何差异证据。
  • 对比图分析中无一比较达到统计学显著,需进一步头对头试验证实。

核心结论

  • 皮下英夫利西单抗在炎症性肠病中与高疗效率相关,可能较静脉制剂提供额外临床获益。
  • 作者认为这应使患者和临床医生对在炎症性肠病中使用皮下英夫利西单抗更有信心。
  • 需进一步头对头试验来确认两种制剂之间的相对疗效。

研究设计与样本

  • 系统综述与网状荟萃分析,检索结果截至2024年8月。
  • 共纳入9项研究、2519例患者,其中克罗恩病846例(33.6%),溃疡性结肠炎1673例(66.4%)。
  • 采用累积排名曲线下面积(SUCRA)、后验概率和对比图计算比较疗效。
  • 评估结局为第30周和第54周的临床应答、临床缓解和内镜缓解。

主要发现

  • SUCRA分析中皮下英夫利西单抗在所有比较中排名第一。
  • 后验概率模型显示皮下制剂在临床应答(30周)和临床缓解(30周及54周)方面有强或极强 superiority 证据。
  • 第54周临床应答方面皮下制剂仅有中等强度证据。
  • 内镜缓解(54周)方面无任何差异证据。
  • 对比图分析中无一比较达到统计学显著。

临床怎么用

  • 作者结论认为皮下英夫利西单抗可能较静脉制剂提供临床获益,应使患者和临床医生对其使用更有信心。
  • 作者建议需进一步头对头试验确认两种制剂的相对疗效。

局限性

  • 原文未报告局限性。
  • 作者在结论中指出需进一步头对头试验来确认两种制剂之间的相对疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Subcutaneous infliximab may provide multiple benefits over intravenous formulations. However, there is uncertainty about the relative efficacy in inflammatory bowel disease (IBD). AIM: To evaluate the relative efficacy of intravenous versus subcutaneous infliximab in patients with IBD using clinical response, clinical remission, and endoscopic remission outcomes at 30- and 54-week outcomes. METHODS: We conducted a systematic review and network meta-analysis with results up to August 2024. We calculated comparative efficacy using surface under the cumulative ranking curve (SUCRA), posterior probability, and contrast plots. RESULTS: A total of 9 studies with 2519 patients met the selection criteria for inclusion; 33.6% (846/2519) of patients had Crohn's disease and 66.4% (1673/2519) had ulcerative colitis. Via SUCRA analysis, subcutaneous infliximab was ranked first in all comparisons. Via posterior probability modelling, there was strong or very strong evidence of superiority with subcutaneous over intravenous infliximab for clinical response (30-week outcomes), clinical remission (30- and 54-week outcomes), although with moderate evidence for clinical response at 54 weeks, and no evidence of any difference for endoscopic remission (54 weeks). Via contrast plot analysis, no comparison reached statistical significance. CONCLUSION: Subcutaneous infliximab is associated with high efficacy rates in IBD. Subcutaneous infliximab may offer clinical benefit above the intravenous formulation. This should provide patients and clinicians with confidence in using subcutaneous infliximab in IBD. Further head-to-head trials are needed to confirm the relative efficacy between these formulations.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chetwood JD, Arzivian A, Tran Y, et al. Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2025. PMID: 40641122. doi:10.1111/apt.70267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。